-
公开(公告)号:US20250020656A1
公开(公告)日:2025-01-16
申请号:US18784141
申请日:2024-07-25
Applicant: AJINOMOTO CO., INC.
Inventor: Naoko ARASHIDA , Rumi NISHIMOTO , Kazutaka SHIMBO , Hidehiro NAKAMURA , Natsumi NISHIKATA , Akira IMAIZUMI
IPC: G01N33/68 , G01N33/574 , G16H50/20
Abstract: An evaluating method includes an evaluating step of evaluating a state of lung cancer for a subject to be evaluated using a concentration value of at least one of Homoarginine, GABA, 3-Me-His, ADMA, Spermine, Spermidine, Cystathionine, Sarcosine, aAiBA, bAiBA, Putrescine, N-Acetyl-L-lys, Hypotaurine, bABA, and Ethylglycine in blood of the subject.
-
2.
公开(公告)号:US20180017570A1
公开(公告)日:2018-01-18
申请号:US15715389
申请日:2017-09-26
Applicant: AJINOMOTO CO., INC.
Inventor: Naoko ARASHIDA , Rumi NISHIMOTO , Kazutaka SHIMBO , Hidehiro NAKAMURA , Natsumi NISHIKATA , Akira IMAIZUMI
IPC: G01N33/68 , G01N33/574 , G06F19/00
CPC classification number: G01N33/6812 , G01N33/57423 , G01N2800/56 , G06F19/3418 , G16H50/20
Abstract: An evaluating method includes an evaluating step of evaluating a state of lung cancer for a subject to be evaluated using a concentration value of at least one of Homoarginine, GABA, 3-Me-His, ADMA, Spermine, Spermidine, Cystathionine, Sarcosine, aAiBA, bAiBA, Putrescine, N-Acetyl-L-lys, Hypotaurine, bABA, and Ethylglycine in blood of the subject.
-
公开(公告)号:US20240277783A1
公开(公告)日:2024-08-22
申请号:US18631361
申请日:2024-04-10
Applicant: Ajinomoto Co., Inc.
Inventor: Riku USAMI , Miku TOYAZAKI , Hidehiro NAKAMURA , Yoshihiko MATSUDA
IPC: A61K35/744 , A61K35/747 , C07K14/50 , C12N15/74
CPC classification number: A61K35/744 , A61K35/747 , C07K14/503 , C12N15/746 , C07K2319/10
Abstract: Provided herein is a technology whereby a heterologous protein can be expressed in a bacterium which does not have an endogenous Tat system secretion machine. The present specification discloses a bacterium such as bifidobacteria, lactococci, and staphylococci which has been modified to express a heterologous Tat protein. The bacterium has the ability to produce and secrete a heterologous protein.
-
公开(公告)号:US20240091185A1
公开(公告)日:2024-03-21
申请号:US18514387
申请日:2023-11-20
Applicant: AJINOMOTO CO., INC.
Inventor: Hidehiro NAKAMURA , Noriko KAWASAKI , Yasuko KAWAMATA , Akihiko KITAMURA , Ryosei SAKAI , Fumika TAKEUCHI
IPC: A61K31/198 , A61K31/685 , A61P25/28
CPC classification number: A61K31/198 , A61K31/685 , A61P25/28
Abstract: Compositions, containing glycine and serine and having a content ratio of glycine to serine (glycine/serine) of not less than 0.6 in weight ratio are effective for improving cognitive function, and have an effective preventive or improving effect on a decline in cognitive function and cognitive dysfunction, are highly safe, and enable continuous ingestion or administration.
-
公开(公告)号:US20190228844A1
公开(公告)日:2019-07-25
申请号:US16373427
申请日:2019-04-02
Applicant: AJINOMOTO CO., INC.
Inventor: Hidehiro NAKAMURA , Natsumi NISHIKATA , Akira IMAIZUMI , Kazutaka SHIMBO , Naoko ARASHIDA , Rumi NISHIMOTO
IPC: G16C20/70
Abstract: An evaluating method includes an evaluating step of evaluating a state of colorectal cancer for a subject to be evaluated using (i) a concentration value of at least one metabolite of bABA, N-Me-bABA, 1-Me-His, aABA, Aminoadipic acid, bAiBA, Cadaverine, Ethylglycine, GABA, Homoarginine, Hypotaurine, Kinurenine, N6-Acetyl-L-Lys, Putrescine, Serotonin, Spermidine, Spermine, ADMA, Homocitrulline, 3-Me-His, Hydroxyproline, Phosphoethanolamine, SDMA, Acylcarnitine (13:1), and EPA in blood of the subject or (ii) a value of a formula calculated using the concentration value of the metabolite and the formula including an explanatory variable to be substituted with the concentration value of the metabolite.
-
公开(公告)号:US20190227071A1
公开(公告)日:2019-07-25
申请号:US16373193
申请日:2019-04-02
Applicant: AJINOMOTO CO., INC.
Inventor: Hidehiro NAKAMURA , Natsumi NISHIKATA , Akira IMAIZUMI , Kazutaka SHIMBO , Naoko ARASHIDA , Rumi NISHIMOTO
IPC: G01N33/574 , G01N33/49 , G01N33/487
Abstract: An evaluating method includes an evaluating step of evaluating a state of pancreatic cancer for a subject to be evaluated using (i) a concentration value of at least one metabolite of N-Me-bABA, bABA, GABA, N6-Acetyl-L-Lys, 1-Me-His, aABA, Aminoadipic acid, bAiBA, Cadaverine, Ethylglycine, Homoarginine, Hypotaurine, Kinurenine, Putrescine, Serotonin, Spermidine, Spermine, ADMA, Homocitrulline, 3-Me-His, Hydroxyproline, Phosphoethanolamine, Acylcarnitine (13:1), and EPA in blood of the subject or (ii) a value of a formula calculated using the concentration value of the metabolite and the formula including an explanatory variable to be substituted with the concentration value of the metabolite.
-
-
-
-
-